Hina Khan, MD
Hematology & Oncology · Providence, RINPI 1356662803
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $24,812 of the $33,546 with a category attached, or 74.0%. 17 manufacturers reported payments, led by AstraZeneca at 40.0% of the total. Among hematology & oncology clinicians in RI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 48 payments — averaging $698.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$13K
- Eli Lilly$4K
- E.r. Squibb & Sons, L.L.C.$3K
- Daiichi Sankyo Inc.$3K
- Regeneron Healthcare Solutions, Inc.$2K
- Sanofi$2K
- plus $5K from 11 others
Across 2 payments — averaging $39,525 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$79K
What the payments were for
- Consulting fees$24,81274%
- Speaking & faculty fees$5,48016%
- Travel & lodging$1,2714%
- Food & beverage$1,9376%
- Education$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 17 | $13,403 |
| Eli Lilly | 3 | $4,438 |
| E.r. Squibb & Sons, L.L.C. | 3 | $3,485 |
| Daiichi Sankyo Inc. | 3 | $2,820 |
| Regeneron Healthcare Solutions, Inc. | 2 | $2,307 |
| Sanofi | 1 | $2,268 |
| Mirati Therapeutics, Inc. | 1 | $2,188 |
| Boehringer Ingelheim | 2 | $1,612 |
| Jazz Pharmaceuticals Inc. | 2 | $251 |
| Johnson & Johnson | 1 | $150 |
| Regeneron | 1 | $148 |
| Astrazeneca UK Limited | 1 | $135 |
| Genentech USA, Inc. | 2 | $114 |
| Medtronic | 2 | $106 |
| Agile Therapeutics, Inc. | 4 | $65 |
| Pfizer | 2 | $45 |
| Integra Lifesciences Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$33,546 in reported general payments places this provider in the 90th percentile of 68 hematology & oncology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dexamethasone | 43 | $380 |
| Prochlorperazine Maleate | 38 | $374 |
| Ondansetron Hcl | 40 | $352 |
| Nystatin | 15 | $309 |
| Oxycodone Hcl | 13 | $191 |
| Levothyroxine Sodium | 15 | $183 |
| Prednisone | 13 | $59 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Providence
- William SikovProvidence$156K
- Ritesh RathoreProvidence$148K
- Anthony MegaProvidence$65K
- Adam OlszewskiProvidence$63K
- Peter BarthProvidence$29K
- Thomas OllilaProvidence$19K
- John ReaganProvidence$18K
- Jennifer GassProvidence$16K
- Matthew HadfieldProvidence$10K
- Humera KhurshidProvidence$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.